

Financial news for EXEL dated on 2020-06-01: Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to \$32

Financial news for EXEL dated on 2020-05-14: Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.

Financial news for EXEL dated on 2020-05-14: SunTrust Robinson Humphrey Maintains Buy on Exelixis, Raises Price Target to \$40

Financial news for EXEL dated on 2020-05-13: Exelixis Reports Results From COSMIC-021 Trial Of Cabozantinib In Combo With Atezolizumab In Multiple Advanced Solid Tumor Types

Financial news for EXEL dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for EXEL dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for EXEL dated on 2020-05-06: BMO Capital Maintains Market Perform on Exelixis, Raises Price Target to \$27

Financial news for EXEL dated on 2020-05-06: Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to \$21

Financial news for EXEL dated on 2020-05-05: Exelixis Q1 Adj. EPS \$0.190 Beats \$0.130 Estimate, Sales \$226.900M Beat \$214.940M Estimate

Financial news for EXEL dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for EXEL dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for EXEL dated on 2020-05-01: Cramer Weighs In On Cracker Barrel, UPS And More

Financial news for EXEL dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for EXEL dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for EXEL dated on 2020-04-24: Stocks That Hit 52-Week Highs On Friday

Financial news for EXEL dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for EXEL dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for EXEL dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for EXEL dated on 2020-04-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for EXEL dated on 2020-04-22: The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership

Financial news for EXEL dated on 2020-04-21: Exelixis shares are trading higher after Oppenheimer maintained an Outperform rating on the company's stock and raised its price target from \$25 to \$28.

Financial news for EXEL dated on 2020-04-21: Oppenheimer Maintains Outperform on Exelixis, Raises Price Target to \$28

Financial news for EXEL dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for EXEL dated on 2020-04-21: 78 Biggest Movers From Yesterday

Financial news for EXEL dated on 2020-04-20: Needham Raises Exelixis Inc. Price

Target From \$28 To \$33

Financial news for EXEL dated on 2020-04-20: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for EXEL dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for EXEL dated on 2020-04-20: Exelixis shares are trading higher after the company announced the results from its Phase 3 CheckMate -9ER Trial met the primary endpoint.

Financial news for EXEL dated on 2020-04-20: Bristol Myers Squibb And Exelixis Announce Topline Results From Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo In Combination With CABOMETYX In Previously Untreated Advanced Renal Cell Carcinoma; Study Met Primary Endpoint

Financial news for EXEL dated on 2020-03-25: Exelixis Earlier Announces Partner Takeda Receives Approval In Japan For CABOMETYX Tablets For The Treatment Of Curatively Unresectable Or Metastatic Renal Cell Carcinoma

Financial news for EXEL dated on 2020-03-25: The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down

Financial news for EXEL dated on 2020-03-25: 30 Stocks Moving in Wednesday's Pre-Market Session

Financial news for EXEL dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for EXEL dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for EXEL dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for EXEL dated on 2020-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2020

Financial news for EXEL dated on 2020-03-04: Barclays Initiates Coverage On Exelixis with Overweight Rating, Announces \$26 Price Target

Financial news for EXEL dated on 2020-03-02: Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors

Financial news for EXEL dated on 2020-02-26: Stifel Maintains Hold on Exelixis, Raises Price Target to \$23

Financial news for EXEL dated on 2020-02-26: BMO Capital Maintains Market Perform on Exelixis, Raises Price Target to \$20

Financial news for EXEL dated on 2020-02-26: Exelixis shares are trading lower after the company reported worse-than-expected Q4 sales results. The company also issued FY20 sales guidance below estimates.

Financial news for EXEL dated on 2020-02-26: 44 Stocks Moving in Wednesday's Pre-Market Session

Financial news for EXEL dated on 2020-02-25: 14 Stocks Moving In Tuesday's After-Hours Session

Financial news for EXEL dated on 2020-02-25: Exelixis shares are trading lower after the company reported worse-than-expected Q4 sales results. The company also issued FY20 sales guidance below estimates.

Financial news for EXEL dated on 2020-02-25: Exelixis Sees FY20 Sales \$850M-\$900M vs \$944M Estimate

Financial news for EXEL dated on 2020-02-25: Exelixis Q4 EPS \$0.26 Beats \$0.16 Estimate, Sales \$240.3M Miss \$240.52M Estimate

Financial news for EXEL dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for EXEL dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for EXEL dated on 2020-02-13: The Daily Biotech Pulse: Deciphera

Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for EXEL dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for EXEL dated on 2020-02-10: Exelixis Highlights Results For Cabozantinib In Combo With Ztezolizumab In Metastatic Castration-Resistant Prostate Cancer

Financial news for EXEL dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for EXEL dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for EXEL dated on 2020-01-29: The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut

Financial news for EXEL dated on 2020-01-29: Exelixis Partner Takeda Files NDA in Japan for CABOMETYX for Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2020-01-24: Exelixis shares are trading lower after the company announced phase 1/2 clinical trial results from the combination of cabozantinib and nivolumab.

Financial news for EXEL dated on 2020-01-24: Exelixis Reports Results For Combo Of Cabozantinib, Nivolumab With Or Without Ipilimumab In Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2020-01-14: Exelixis shares are trading higher. The stock moved higher following unusual interest in next month's \$19 call contract.

Financial news for EXEL dated on 2020-01-14: Exelixis Option Alert: Fri \$19 Calls Sweep (20) near the Ask: 1063 @ \$0.7 vs 2183 OI; Earnings 2/11 After Close [est] Ref=\$19.31

Financial news for EXEL dated on 2020-01-13: Benzinga's Top Upgrades, Downgrades For January 13, 2020

Financial news for EXEL dated on 2020-01-13: SunTrust Robinson Humphrey Initiates Coverage On Exelixis with Buy Rating, Announces \$31 Price Target

Financial news for EXEL dated on 2020-01-13: Bank of America Reiterates Buy on Exelixis, Lowers Price Target to \$21

Financial news for EXEL dated on 2020-01-13: 25 Stocks Moving in Monday's Pre-Market Session

Financial news for EXEL dated on 2020-01-12: Exelixis Sees FY 2019 Revenue ~\$972M vs \$957.49M Est; Q4 Revenue \$245M vs \$231.02M Est

Financial news for EXEL dated on 2020-01-12: Exelixis Announces Anticipated Timelines for Data Readouts From Six Cabozantinib Potentially Label-enabling Clinical Studies and Up to Three New Potential Ind Candidates

Financial news for EXEL dated on 2020-01-07: 20 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2020-01-07: Exelixis Further Prostate Cancer Cohort In Phase 1b COSMIC-021 Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Advanced Solid Tumors

Financial news for EXEL dated on 2019-12-19: Exelixis Reports Collaboration For 3 Phase 3 Combo Trials For Patients With Advanced Solid Tumors

Financial news for EXEL dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for EXEL dated on 2019-12-13: Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

Financial news for EXEL dated on 2019-12-10: Exelixis shares are trading higher on seemingly no company-specific news.

Financial news for EXEL dated on 2019-12-04: Exelixis shares are trading higher. Not seeing any news to justify the price action.

Financial news for EXEL dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for EXEL dated on 2019-11-13: Exelixis shares are trading higher. Not seeing any news to justify the price action.

Financial news for EXEL dated on 2019-11-12: Exelixis Partner Ipsen Announces Health Canada Approval Of CABOMETYX Tablets For The Treatment Of Patients With Previously Treated Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2019-11-08: Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

Financial news for EXEL dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for EXEL dated on 2019-10-31: Exelixis shares are trading lower despite reporting strong Q3 earnings beat.

Financial news for EXEL dated on 2019-10-31: Exelixis Reported Yesterday Q3 EPS \$0.34 Beats \$0.19 Estimate, Sales \$271.703M Beat \$227.82M Estimate

Financial news for EXEL dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for EXEL dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for EXEL dated on 2019-10-15: Guggenheim Maintains Buy on Exelixis, Lowers Price Target to \$25

Financial news for EXEL dated on 2019-10-09: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 09, 2019

Financial news for EXEL dated on 2019-10-08: BMO Capital Maintains Market Perform on Exelixis, Lowers Price Target to \$19

Financial news for EXEL dated on 2019-10-04: Exelixis shares are trading lower despite no company-specific news. The stock has dropped approximately 15% over the past month.

Financial news for EXEL dated on 2019-09-26: Exelixis Says Intends To Defend Intellectual Property Rights For CABOMETYX

Financial news for EXEL dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for EXEL dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for EXEL dated on 2019-08-30: Pete Najarian Sees Unusual Options Activity In Exelixis

Financial news for EXEL dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for EXEL dated on 2019-08-16: Exelixis Option Alert: Sep 20 \$24 Calls Sweep (40) near the Ask: 1187 @ \$0.6 vs 103 OI; Ref=\$21.42

Financial news for EXEL dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for EXEL dated on 2019-08-16: Exelixis Option Alert: Sep 20 \$22 Calls Sweep (31) near the Ask: 1501 @ \$1.004 vs 6027 OI; Ref=\$21.095

Financial news for EXEL dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for EXEL dated on 2019-07-31: Exelixis Reports Exclusive

Collaboration, Option, License Deal With Aurigene For Discovery, Development Of Novel Therapies For Cancer

Financial news for EXEL dated on 2019-07-31: Exelixis Q2 EPS \$0.29 Beats \$0.25 Estimate, Sales \$240.275M Beat \$227.8M Estimate

Financial news for EXEL dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for EXEL dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for EXEL dated on 2019-07-26: 30 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for EXEL dated on 2019-07-15: Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Patients With Advanced Solid Tumors, Says Adding 4 Cohorts Due to Encouraging Early Data

Financial news for EXEL dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for EXEL dated on 2019-06-21: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for EXEL dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for EXEL dated on 2019-06-21: From 8K Filing Late Thursday: Exelixis Said on June 19 Informed By Genentech, Imspirel70, Phase 3 Trial Evaluating Combination of Cobimetinib & Atezolizumab Did Not Meet Primary Endpoint

Financial news for EXEL dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for EXEL dated on 2019-05-16: Exelixis, Iconic Therapeutics Report Exclusive Option, License Deal For Novel Antibody-Drug Conjugate Program

Financial news for EXEL dated on 2019-05-13: Exelixis' Collaborator Daiichi Sankyo Launches Minnebrol Tablets in Japan; Triggers \$20MMilestone Payment to Exelixis

Financial news for EXEL dated on 2019-05-10: Jim Cramer Weighs In On Zebra Technologies, Exelixis And More

Financial news for EXEL dated on 2019-05-01: Exelixis Initiates Phase 3 Pivotal Trial Of Cabozantinib In Combination With Nivolumab And Ipilimumab Versus Nivolumab And Ipilimumab In Previously Untreated Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2019-05-01: Exelixis Q1 EPS \$0.27, Inline, Sales \$215.487M Up From \$212.346M YoY

Financial news for EXEL dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for EXEL dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for EXEL dated on 2019-04-25: Exelixis Says Checkmate 9ER Recently Completed Enrollment

Financial news for EXEL dated on 2019-04-25: Exelixis' Highlights That Its Partner, Takeda, Filed New Drug Application In Japan For CABOMETYX For Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2019-03-18: Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

Financial news for EXEL dated on 2019-03-18: Benzinga's Top Upgrades, Downgrades For March 16, 2019

Financial news for EXEL dated on 2019-03-18: Morgan Stanley Upgrades Exelixis to Equal-Weight

Financial news for EXEL dated on 2019-02-22: BMO Capital Initiates Coverage On

Exelixis with Market Perform Rating, Announces \$23 Price Target

Financial news for EXEL dated on 2019-02-15: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for EXEL dated on 2019-02-13: Exelixis shares are trading higher after the company reported Q4 EPS of \$0.37, beating the \$0.24 consensus estimate and sales of \$228.6 million beating the \$188.76 million estimate; the company said it would initiate Phase 1 clinical development of XL092.

Financial news for EXEL dated on 2019-02-13: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EXEL dated on 2019-02-13: The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

Financial news for EXEL dated on 2019-02-12: 7 Stocks Moving In Tuesday's After-Hours Session

Financial news for EXEL dated on 2019-02-12: Exelixis Reports Will Initiate Phase 1 Clinical Development Of XL092

Financial news for EXEL dated on 2019-02-12: Exelixis Q4 EPS \$0.37 Beats \$0.24 Estimate, Sales \$228.6M Beat \$188.76M Estimate

Financial news for EXEL dated on 2019-02-12: Q4 Earnings Preview For Exelixis

Financial news for EXEL dated on 2019-02-12: The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares

Financial news for EXEL dated on 2019-02-12: Earnings Scheduled For February 12, 2019

Financial news for EXEL dated on 2019-02-10: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for EXEL dated on 2019-01-14: Exelixis Announces FDA Approval Of CABOMETYX Tablets For Previously Treated Hepatocellular Carcinoma

Financial news for EXEL dated on 2019-01-13: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for EXEL dated on 2019-01-08: Exelixis Announces That Its Partner Daiichi Sankyo Company (DSNKY) Received Approval From The Japanese Ministry of Health For The Marketing Of Esaxerenone Tablets, MINNEBRO As A Treatment For Patients With Hypertension

Financial news for EXEL dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for EXEL dated on 2018-12-05: Exelixis, Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for EXEL dated on 2018-11-15: Exelixis' Partner Ipsen Receives EC Approval for CABOMETYX Tablets for Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

Financial news for EXEL dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for EXEL dated on 2018-11-02: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for EXEL dated on 2018-11-02: 34 Stocks Moving In Friday's Pre-Market Session

Financial news for EXEL dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for EXEL dated on 2018-11-01: Exelixis, Inc. Q3 EPS \$0.41 Beats \$0.19 Estimate, Sales \$225.397M Beat \$172.59M Estimate

Financial news for EXEL dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for EXEL dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for EXEL dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Asserzio

Financial news for EXEL dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for EXEL dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for EXEL dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for EXEL dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for EXEL dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for EXEL dated on 2018-10-22: 11 Stocks That Moved From ESMO 2018

Financial news for EXEL dated on 2018-10-22: Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2018-10-20: Exelixis Announces Cabozantinib Was Associated With Improved Overall Survival and Progression-free Survival Irrespective of Pd-11 Expression in Cabosun and Meteor Trials at ESMO 2018

Financial news for EXEL dated on 2018-10-08: Exelixis Initiates Phase 3 Pivotal Trial Of Cabozantinib In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy

Financial news for EXEL dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for EXEL dated on 2018-09-21: Exelixis' Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX Tablets for Previously Treated Hepatocellular Carcinoma

Financial news for EXEL dated on 2018-09-19: Exelixis' Partner, Ipsen, Announces Health Canada's Approval For CABOMETYX Tablets In Advanced Renal Cell Carcinoma; Approval Was Based On Improvement In Overall Survival, Progression-Free Survival And Objective Response Rate

Financial news for EXEL dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for EXEL dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for EXEL dated on 2018-09-17: Goldman Sachs Initiates Coverage On Exelixis with Neutral Rating, Announces \$22 Price Target

Financial news for EXEL dated on 2018-09-14: Stocks Which Set New 52-Week Low Yesterday, September 13th

Financial news for EXEL dated on 2018-09-13: Stocks Which Set New 52-Week Low Yesterday, September 12th

Financial news for EXEL dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for EXEL dated on 2018-09-10: A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others

Financial news for EXEL dated on 2018-09-10: Morgan Stanley Initiates Coverage On Exelixis with Underweight Rating, Announces \$19 Price Target

Financial news for EXEL dated on 2018-09-07: Exelixis Announces New Recommendations For CABOMETYX Tablets In Updated Comprehensive Cancer Network Clinical Practice Guidelines

Financial news for EXEL dated on 2018-09-07: Jim Cramer Weighs In On CarMax, AbbVie And More

Financial news for EXEL dated on 2018-08-22: Stocks Which Set New 52-Week Low

Yesterday, August 21st

Financial news for EXEL dated on 2018-08-21: Stocks Which Set New 52-Week Low Tues., Aug. 21, 2018

Financial news for EXEL dated on 2018-08-21: The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

Financial news for EXEL dated on 2018-08-21: 41 Biggest Movers From Yesterday

Financial news for EXEL dated on 2018-08-20: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for EXEL dated on 2018-08-20: Exelixis shares are down 6.8%; Not yet seeing any news to justify price action.

Financial news for EXEL dated on 2018-08-01: Exelixis Q2 EPS \$0.28 Beats \$0.16 Estimate, Sales \$186.11M Beat \$157.37M Estimate

Financial news for EXEL dated on 2018-08-01: Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

Financial news for EXEL dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for EXEL dated on 2018-07-26: BZ NOTE On Exelixis Spike Higher: Traders Likely Viewing Co.'s Renal Cancer Treatment Optimistically Following Comment on Bristol-Myers Q2 Earnings Conference Call It Will Receive Negative CHMP Opinion For OPDIVO, A Potential Renal Cancer Treatment

Financial news for EXEL dated on 2018-07-26: Exelixis Shares Spike 2.8% Higher, Could Be Related To Chatter Of Negative CHMP Opinion For Renal Cell Carcinoma Treatment Discussed On Bristol-Myers Q2 Earnings Conference Call

Financial news for EXEL dated on 2018-07-19: William Blair Views 4 Biotech/Pharma Stocks As 'Top Picks': Adamas Pharma, Aclaris Therapeutics, Bidelivery Sciences, Exelixis

Financial news for EXEL dated on 2018-07-04: Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

Financial news for EXEL dated on 2018-06-27: 54 Biggest Movers From Yesterday

Financial news for EXEL dated on 2018-06-26: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for EXEL dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for EXEL dated on 2018-06-26: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2018-06-25: S&P Dow Jones Indices Announces 'Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400'

Financial news for EXEL dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for EXEL dated on 2018-06-03: Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at #ASCO2018

Financial news for EXEL dated on 2018-06-01: UPDATE: Exelixis Says 10 New Trial Cohorts Added To Expansion Phase Of Combo Trial For Cabozantinib

Financial news for EXEL dated on 2018-06-01: Exelixis Reports Further Expansion To Research Protocol For Phase 1b COSMIC-021 Trial Of Cabozantinib In Combo With Anti-PD-L1 Immunotherapy In Patients With Locally-Advanced Or Metastatic Solid Tumors

Financial news for EXEL dated on 2018-05-30: Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immuteq Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA

Financial news for EXEL dated on 2018-05-29: Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application For CABOMETYX (cabozantinib) In Previously Treated Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2018-05-26: The Week Ahead In Biotech: ASCO Presentations In The Spotlight



Financial news for EXEL dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ipsen And More

Financial news for EXEL dated on 2018-05-17: Exelixis' Partner Ipsen Announces EC Approval of CABOMETYX for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma; Triggers \$50M Milestone Payment to Exelixis

Financial news for EXEL dated on 2018-05-11: 55 Biggest Movers From Yesterday

Financial news for EXEL dated on 2018-05-10: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for EXEL dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for EXEL dated on 2018-05-10: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for EXEL dated on 2018-05-10: Exelixis Says IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer did Not Meet Primary Endpoint

Financial news for EXEL dated on 2018-05-04: Jim Cramer Shares His Thoughts On Blackstone, Celgene And More

Financial news for EXEL dated on 2018-05-03: Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

Financial news for EXEL dated on 2018-05-02: Exelixis Q1 EPS \$0.37 Beats \$0.13 Estimate, Sales \$212.34M Beat \$134.03M Estimate

Financial news for EXEL dated on 2018-05-02: Exelixis, Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer

Financial news for EXEL dated on 2018-05-02: Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

Financial news for EXEL dated on 2018-04-09: Shares Of Exelixis Plunge After Report Its MODUL Trial Suspended Following A Review Of One Of Its Cohorts

Financial news for EXEL dated on 2018-03-28: For Now, Traders Endorse Biotech Rally

Financial news for EXEL dated on 2018-03-28: Exelixis' Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX for Previously Treated Advanced Hepatocellular Carcinoma

Financial news for EXEL dated on 2018-03-23: Exelixis Partner Ipsen Earlier Received Positive Opinion On CABOMETYX For Renal Cell Carcinoma From Committee For Medicinal Products For Human Use; Opinion Will Be Reviewed By European Commission For Approval

Financial news for EXEL dated on 2018-03-15: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX

Financial news for EXEL dated on 2018-02-27: Exelixis Earlier Announced Partner Daiichi Sankyo's Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan

Financial news for EXEL dated on 2018-02-27: Benzinga's Top Upgrades, Downgrades For February 27, 2018

Financial news for EXEL dated on 2018-02-27: Oppenheimer Upgrades Exelixis to Outperform

Financial news for EXEL dated on 2018-02-26: Exelixis Reports Q4 EPS \$0.12, Inline, Sales \$120.1M vs \$120.3M Est.

Financial news for EXEL dated on 2018-02-26: Exelixis Q4 Earnings Outlook

Financial news for EXEL dated on 2018-02-21: RBC Capital Global Healthcare Conference Begins Today, Presenters Include: Chemed, Revance, Eagle Pharma, Enanta, Gilead, TransEnterix, Immunogen, and Incyte

Financial news for EXEL dated on 2018-02-13: Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib, Showed 54% Objective Response Rate And 43% Stable Disease Rate Among 35 Evaluable Patients

Financial news for EXEL dated on 2018-02-07: Exelixis Gives an Update on its Phase 1 Trial for Cabozantinib in Combination with Nivolumab

Financial news for EXEL dated on 2018-01-21: Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib and Atezolizumab in Metastatic Colorectal Cancer at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Financial news for EXEL dated on 2018-01-16: STAT News' Adam Feuerstein Tweets '\$EXEL data look basically in line with expectations.'

Financial news for EXEL dated on 2018-01-16: Exelixis Shares Resume, Up ~1.9% After Hours

Financial news for EXEL dated on 2018-01-16: Exelixis Shares To Resume Trade At 5:30 p.m. EST

Financial news for EXEL dated on 2018-01-16: Exelixis and Ipsen Announce Phase 3 Trial Shows Cabozantinib Met Primary Endpoint, To Submit NDA In Q1 18

Financial news for EXEL dated on 2018-01-16: Exelixis Shares Halted News Pending

Financial news for EXEL dated on 2018-01-15: Diplomat Pharmacy Dispensing Exelixis CABOMETYX Now with Expanded Indication

Financial news for EXEL dated on 2018-01-08: Exelixis Enters Exclusive Licensing Agreement With StemSynergy For CK1a Activator Program, Will Pay StemSynergy \$3M Upfront And Up To \$3.5M In R&D Funding, In Addition To Variety Of Milestone Payments

Financial news for EXEL dated on 2018-01-04: Exelixis Says 4 New Trial Cohorts, Including NSCLC, CRPC, Added To Expansion Phase Of Combo Trial For Cabozantinib with Atezolizumab

Financial news for EXEL dated on 2017-12-20: 28 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EXEL dated on 2017-12-19: UPDATE: Exelixis Says Co. Is 'prepared to fully support expanded indication immediately'

Financial news for EXEL dated on 2017-12-19: UPDATE: Exelixis Highlights PDUFA Date For CABOMETYX Feb. 15, 2018

Financial news for EXEL dated on 2017-12-19: Exelixis Reports FDA Approval Of CABOMETYX Tablets For Previously Untreated Advanced Renal Cell Carinoma

Financial news for EXEL dated on 2017-11-14: Stifel 2017 Healthcare Conference Begins Today, Presenters Include: Seres Therapeutics, Verastem, TherapeuticsMD, Aerie Pharmaceuticals, Mednax, Celgene, TransEnterix, Exelixis, Tandem Diabetes Care and Masimo

Financial news for EXEL dated on 2017-11-02: 52 Stocks Moving In Thursday's Mid-Day Session

Financial news for EXEL dated on 2017-11-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for EXEL dated on 2017-11-01: Exelixis Reports Q3 Adj. EPS \$0.26 vs \$(0.04) In Same Qtr. Last Year, Sales \$152.5M vs \$62.2M YoY

Financial news for EXEL dated on 2017-10-17: 35 Biggest Movers From Yesterday

Financial news for EXEL dated on 2017-10-16: Benzinga's Option Alert Recap From October 16

Financial news for EXEL dated on 2017-10-16: Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge

Financial news for EXEL dated on 2017-10-16: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for EXEL dated on 2017-10-16: Mid-Day Market Update: TransEnterix Climbs Following FDA Clearance Of Senhance Surgical Robot; TG Therapeutics Shares Decline

Financial news for EXEL dated on 2017-10-16: Mid-Morning Market Update: Markets Open Higher; Charles Schwab Earnings Top Views

Financial news for EXEL dated on 2017-10-16: Exelixis Option Alert: Feb 16 \$28 Puts Sweep (16) at the Ask: 500 @ \$3.0 vs 57 OI; Ref=\$30.07

Financial news for EXEL dated on 2017-10-16: Here's Why Exelixis Is Trading Higher By 20%

Financial news for EXEL dated on 2017-10-16: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for EXEL dated on 2017-10-16: A Peek Into The Markets: U.S. Stock Futures Edge Higher; Netflix Earnings In Focus

Financial news for EXEL dated on 2017-10-16: Exelixis Granted Priority Review for CABOMETYX by the FDA

Financial news for EXEL dated on 2017-10-16: Exelixis' Phase 3 CELESTIAL Trial Met its Primary Endpoint, Company to Submit a Supplemental NDA in Q1 2018

Financial news for EXEL dated on 2017-10-04: Exelixis to Receive \$10M Milestone Payment from Bristol-Myers for Submission of Clinical Trial Authorization for ROR?t Inverse Agonist Program

Financial news for EXEL dated on 2017-09-25: Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma

Financial news for EXEL dated on 2017-09-22: Exelixis Shares Sell Off ~12% Fri. As \$28 Resistance Level Holds; Stock Had Been Range Bound Between \$26-\$28 Over Most Of Jul.-Sept.

Financial news for EXEL dated on 2017-09-22: The Street Has Finally Recognized The Exelixis Clinical Program Potential

Financial news for EXEL dated on 2017-09-22: 12 Biggest Mid-Day Losers For Friday

Financial news for EXEL dated on 2017-09-22: Leerink Swann Downgrades Exelixis to Market Perform

Financial news for EXEL dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for EXEL dated on 2017-09-14: RBC Initiates Coverage on 6 Pharma Stocks After Hours

Financial news for EXEL dated on 2017-09-11: Watch These 5 Huge Call Purchases In Monday Trade

Financial news for EXEL dated on 2017-09-10: Ipsen, Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib vs Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017

Financial news for EXEL dated on 2017-09-08: Benzinga's Option Alert Recap From September 8

Financial news for EXEL dated on 2017-09-08: Exelixis Option Alert: Nov 17 \$29 Calls at the Bid: 500 @ \$1.45 vs 163 OI; Ref=\$25.7

Financial news for EXEL dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for EXEL dated on 2017-09-07: 18 Biggest Mid-Day Losers For Thursday

Financial news for EXEL dated on 2017-08-16: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EXEL dated on 2017-08-16: A Peek Into The Markets: U.S. Stock Futures Rise; All Eyes On Fed Minutes

Financial news for EXEL dated on 2017-08-16: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX

Financial news for EXEL dated on 2017-08-03: The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom

Financial news for EXEL dated on 2017-08-03: Deutsche Bank Downgrades Exelixis to Hold

Financial news for EXEL dated on 2017-08-02: Exelixies Reaffirms FY17 Guidance

Financial news for EXEL dated on 2017-08-02: Exelixis W/ Bristol-Myers Squibb Announces Start Of Phase 3 Trial For Cabozantinib in Combinations

Financial news for EXEL dated on 2017-08-02: Exelixis Reports Q2 EPS \$0.06 vs \$0.04 Est., Sales \$99M vs \$85.31M Est.

Financial news for EXEL dated on 2017-07-20: Exelixis Reports Settlement Of Dispute With Genentech Related To Cos.' Collaboration Deal For Cobimetinib

Financial news for EXEL dated on 2017-06-29: Exelixis Shares Up ~2% Over Last Few Mins As Traders Circulating Chatter Co. Could Be Interested In Considering Sale

Financial news for EXEL dated on 2017-06-21: Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide

Financial news for EXEL dated on 2017-06-21: Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations

Financial news for EXEL dated on 2017-06-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for EXEL dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for EXEL dated on 2017-06-19: Exelixis Announces IRC Confirms Cabozantinib Significantly Improved Progression-Free Survival Compared to Sunitinib, U.S. Regulatory Submission Remains on Track for Q3 2017

Financial news for EXEL dated on 2017-06-12: Exelixis Reports Initiation Of Phase 1b Trial Of Cabozantinib In Combo With Atezolizumab In Patients With Locally-Advanced Metastatic Solid Tumors

Financial news for EXEL dated on 2017-06-05: Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data

Financial news for EXEL dated on 2017-05-31: Watch These 8 Huge Call Purchases In Wednesday Trade

Financial news for EXEL dated on 2017-05-30: Option Alert: Exelixis Jul 14.0 Calls Sweep: 503 @ ASK \$5.10: 1788 traded vs 0 OI: Earnings 8/3 After Close (est) \$18.80 Ref

Financial news for EXEL dated on 2017-05-24: Watch These 5 Huge Put Purchases In Wednesday Trade

Financial news for EXEL dated on 2017-05-23: Benzinga's Option Alert Recap From May 23

Financial news for EXEL dated on 2017-05-19: Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss

Financial news for EXEL dated on 2017-05-18: Stifel's ASCO Abstract Cheat Sheet

Financial news for EXEL dated on 2017-05-03: Deutsche Bank Healthcare Conference Begins Today; Presenters Include Synergy Pharma, Exelixis, AbbVie, Collegium Pharma, Zimmer Biomet, Luminex, CRISPR Therapeutics, & Edwards Lifesciences

Financial news for EXEL dated on 2017-05-02: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for EXEL dated on 2017-05-02: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2017-05-01: Exelixis Q1 EPS \$0.05 vs \$(0.01) Est, Sales \$80.89M vs \$65.23M Est

Financial news for EXEL dated on 2017-04-03: Volume Spike in Exelixis

Financial news for EXEL dated on 2017-03-31: Exelixis Shares Up 2%; Needham Earlier Initiated with a Buy Rating, \$28 Price Target

Financial news for EXEL dated on 2017-03-30: Exelixis Shares Down Premarket Following Last Night's After-Hours Announcement Of \$80.1M Debt Repayment

Financial news for EXEL dated on 2017-03-16: Benzinga's Top Upgrades, Downgrades For March 16, 2017

Financial news for EXEL dated on 2017-03-16: Oppenheimer Initiates Coverage On Exelixis With Perform

Financial news for EXEL dated on 2017-03-08: Exelixis Turn Negative Following Circulation Of Journal Of Clinical Oncology Cautious Report On Cabozantinib Earlier

Financial news for EXEL dated on 2017-03-08: Traders Circulating Cautious Article From Journal Of Clinical Oncology Highlighting Exelis Drug Cabozantinib

Financial news for EXEL dated on 2017-03-06: Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Financial news for EXEL dated on 2017-03-05: Exelixis' Cabozantinib Granted FDA Orphan Drug Designation

Financial news for EXEL dated on 2017-03-04: Icahn's (Potential) Move Into Biotech

Financial news for EXEL dated on 2017-02-28: 20 Biggest Mid-Day Losers For Tuesday

Financial news for EXEL dated on 2017-02-28: Benzinga's Top Upgrades, Downgrades For February 28, 2017

Financial news for EXEL dated on 2017-02-28: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2017-02-28: Stifel Nicolaus Downgrades Exelixis To Hold, Raises Price Target to \$22

Financial news for EXEL dated on 2017-02-27: Exelixis Reports Q4 EPS \$0.12 vs. \$(0.01) Est., Sales \$77.58M vs. \$66.5M Est.

Financial news for EXEL dated on 2017-02-27: Exelixis Reprots Clinical Trial Partnership with Roche to Evaluate Cabozantinib and Atezolizumab in Locally Advanced or Metastatic Solid Tumors

Financial news for EXEL dated on 2017-02-22: venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter

Financial news for EXEL dated on 2017-02-10: venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders

Financial news for EXEL dated on 2017-02-06: Benzinga's Option Alert Recap From February 6

Financial news for EXEL dated on 2017-02-06: Option Alert: Exelixis Feb 20.0 Calls Sweep: 508 @ ASK \$1.60: 1448 traded vs 5233 OI: Earnings 2/27 After Close \$20.13 Ref

Financial news for EXEL dated on 2017-01-31: Adam Feuerstein Tweets: \$EXEL down on Takeda cabo licensing deal because Takeda didn't buy the company.

Financial news for EXEL dated on 2017-01-30: UPDATE: Exelixis Received \$50M Upfront Payment, is Eligible for Future Regulatory, Commercial Milestones of \$95M

Financial news for EXEL dated on 2017-01-30: Exelixis Reports Exclusive Licensing Deal with Takeda for Commercialization, Development of Cabozantinib in Japan

Financial news for EXEL dated on 2017-01-30: Benzinga's Option Alert Recap From January 30

Financial news for EXEL dated on 2017-01-30: Option Alert: Exelixis Jan18 50.0 Calls: 500 @ ASK \$2.75: 569 traded vs 891 OI: Earnings 2/23 After Close (est) \$29.44 Ref

Financial news for EXEL dated on 2017-01-25: Watch These 10 Huge Call Purchases In Wednesday Trade

Financial news for EXEL dated on 2017-01-24: Benzinga's Option Alert Recap From January 24

Financial news for EXEL dated on 2017-01-24: Option Alert: Exelixis Mar 22.0 Calls Sweep: 1500 @ ASK \$0.90: 1510 traded vs 19 OI: Earnings 2/28 After Close (est) \$18.04 Ref

Financial news for EXEL dated on 2017-01-23: Watch These 8 Huge Call Purchases In Monday Trade

Financial news for EXEL dated on 2017-01-20: Option Alert: Exelixis Feb 20.0 Calls Sweep: 500 @ ASK \$0.90: 500 traded vs 2179 OI: Earnings 2/28 After Close (est) \$17.79 Ref

Financial news for EXEL dated on 2017-01-17: Watch These 7 Huge Put Purchases In Tuesday Trade

Financial news for EXEL dated on 2017-01-13: Option Alert: Exelixis Feb 18.0 Puts Sweep: 653 @ ASK \$1.55: 3560 traded vs 11k OI: Earnings 2/28 After Close (est) \$19.18 Ref

Financial news for EXEL dated on 2017-01-12: Option Alert: Exelixis Feb 21.0 Calls

Sweep: 667 @ ASK \$1.099: 699 traded vs 246 OI: Earnings 2/28 After Close (est)  
\$18.87 Ref

Financial news for EXEL dated on 2017-01-09: Exelixis Announces Genentech has  
Withdrawn Counterclaim Against Exelixis in Ongoing Jams Arbitration

Financial news for EXEL dated on 2017-01-03: Option Alert: Exelixis Jan \$17 Call;  
2869 @Bid @\$0.40; Ref = \$14.60

Financial news for EXEL dated on 2016-12-23: 6 Best Biotech Stocks Of 2016

Financial news for EXEL dated on 2016-12-22: Exelixis Shares Edge Lower as Traders  
Circulating Journal of Clinical Oncology Article 'Future Challenges for Drug  
Development in Renal Cell Carcinoma'

Financial news for EXEL dated on 2016-12-21: Exelixis, Ipsen Licensing Agreement for  
Commercialization and Development of Cabozantinib to Now Include Canada

Financial news for EXEL dated on 2016-12-19: Watch These 7 Huge Put Purchases In  
Monday Trade

Financial news for EXEL dated on 2016-12-15: Watch These 5 Huge Put Purchases In  
Thursday Trade

Financial news for EXEL dated on 2016-12-14: Option Alert: EXEL Jan17 16.0 Puts  
Sweep: 2644 @ ASK \$1.35: 2654 traded vs 265 OI: Earnings 2/28 After Close (est)  
\$16.29 Ref

Financial news for EXEL dated on 2016-12-07: Mid-Afternoon Market Update: Dow Surges  
250 Points; Oxford Industries Shares Tumble

Financial news for EXEL dated on 2016-12-07: Mid-Day Market Update: Dave & Buster's  
Climbs On Upbeat Results; Sigma Designs Shares Slide

Financial news for EXEL dated on 2016-12-06: 18 Stocks Moving In Tuesday's Pre-Market  
Session

Financial news for EXEL dated on 2016-12-05: What Is The ASH Conference And Why  
Should Biotech Investors Care?

Financial news for EXEL dated on 2016-11-07: Exelixis Announces Presentation of  
Cobimetinib Combination Therapy Data at Society for Melanoma Research 2016 Congress  
That Support Genentech's Planned Phase 3 Pivotal Trials

Financial news for EXEL dated on 2016-11-04: 25 Biggest Mid-Day Gainers For Friday

Financial news for EXEL dated on 2016-11-04: 22 Stocks Moving In Friday's Pre-Market  
Session

Financial news for EXEL dated on 2016-11-03: Exelixis Reports Q3 Loss/Share \$0.04 vs  
\$0.13 Est, Rev \$42.7M vs \$42.86M Est

Financial news for EXEL dated on 2016-11-03: Deutsche Bank Initiates Coverage On  
Exelixis, Inc. - Common Stock at Buy

Financial news for EXEL dated on 2016-10-17: Hearing Money Map Press Recommends  
Exelixis, Inc. As New Buy

Financial news for EXEL dated on 2016-10-11: Option Alert: EXEL Oct \$12 Call; 2707  
@Bid @\$0.97; Ref = \$12.70

Financial news for EXEL dated on 2016-10-10: Exelixis Shares Turn Lower Over Last Few  
Mins, Down ~2% for Session; \$13 May Have Been a Notable Support Level

Financial news for EXEL dated on 2016-10-10: 16 Stocks Moving In Monday's Pre-Market  
Session

Financial news for EXEL dated on 2016-10-10: Exelixis Announces Positive Results from  
Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated  
Advanced Renal Cell Carcinoma Presented at ESMO 2016

Financial news for EXEL dated on 2016-10-07: 18 Biggest Mid-Day Losers For Friday

Financial news for EXEL dated on 2016-10-07: 18 Stocks Moving In Friday's Pre-Market  
Session

Financial news for EXEL dated on 2016-10-07: Exelixis Presents Phase 1 Trial Results  
for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors at  
ESMO 2016

Financial news for EXEL dated on 2016-10-07: Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016

Financial news for EXEL dated on 2016-09-29: Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Financial news for EXEL dated on 2016-09-29: Mid-Day Market Update: Crude Oil Rises Over 2%; Intra-Cellular Therapies Shares Slide

Financial news for EXEL dated on 2016-09-29: Mid-Morning Market Update: Markets Edge Lower; PepsiCo Beats Q3 Expectations

Financial news for EXEL dated on 2016-09-28: Technical Alert: Exelixis Sharply Lower

Financial news for EXEL dated on 2016-09-28: Leerink Out Defending Exelixis, Says Selloff Overdone

Financial news for EXEL dated on 2016-09-28: 12 Biggest Mid-Day Losers For Wednesday

Financial news for EXEL dated on 2016-09-28: Exelixis Shares Trading Down 13.5%, Traders Attributing Weakness In Shares To Cabometyx, Opdivo Data Compared To Other Combinations

Financial news for EXEL dated on 2016-09-28: Exelixis Sells off to Low of \$12.61 on Volume

Financial news for EXEL dated on 2016-09-26: 12 Biggest Mid-Day Gainers For Monday

Financial news for EXEL dated on 2016-09-26: Stocks Hitting 52-Week Highs

Financial news for EXEL dated on 2016-09-26: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for EXEL dated on 2016-09-26: Exelis Gets \$15M Milestone Payment for Initiation of Phase 3 Study

Financial news for EXEL dated on 2016-09-21: Option Alert: EXEL Fri \$14 Calls at the bid: Volume of 5,000 @ 1.351 vs 786 Open Interest

Financial news for EXEL dated on 2016-09-21: Stocks Hitting 52-Week Highs

Financial news for EXEL dated on 2016-09-21: Exelixis Shares Indicated Up ~4% Premarket Amid Recent Pharma M&A, Following Co. Report Tues. Afternoon an Update on CABOZANTINIB Will Be Presented at ESMO '16 Congress on Oct. 10, '16

Financial news for EXEL dated on 2016-09-14: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for EXEL dated on 2016-09-14: Option Alert: Exelixis Jan 20 \$15 Puts at the bid: 2000 @ 3.0 vs. Open Interest 0

Financial news for EXEL dated on 2016-09-14: Stocks Hitting 52-Week Highs

Financial news for EXEL dated on 2016-09-14: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for EXEL dated on 2016-09-14: Exelixis Announces EC Approves CABOMETYX Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy

Financial news for EXEL dated on 2016-09-13: Option Alert: EXEL Jan \$15 Put @Bid @\$4.80; Ref=\$12.44

Financial news for EXEL dated on 2016-09-06: Exelixis Announces Phase 3 Trial Of CELESTIAL Interim Analysis Results; It Is Determined The Study Should Continue Without Modifications

Financial news for EXEL dated on 2016-09-06: Exelixis Pops to High of \$12.05 on Volume

Financial news for EXEL dated on 2016-09-06: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2016-08-05: Watch These 7 Huge Put Purchases In Friday Trade

Financial news for EXEL dated on 2016-08-04: Major Averages Close Thursday's Session Mostly Unchanged

Financial news for EXEL dated on 2016-08-04: 20 Biggest Mid-Day Gainers For Thursday

Financial news for EXEL dated on 2016-08-04: Option Alert: EXEL Jan17 11.0 Puts Sweep: 4497 @ ASK \$1.45: 4594 traded vs 0 OI: \$11.42 Ref

Financial news for EXEL dated on 2016-08-04: Stocks Hitting 52-Week Highs

Financial news for EXEL dated on 2016-08-04: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for EXEL dated on 2016-08-03: After-Hours Gainers Aug. 3, '16: OCUL Up 22%, SQ 14.9%, CBMX 13.5%, AXGN 10%, AVID 8.7%, PODD 8.6%, NSTG 8.3%, JACK 8%, EXEL 7.7%

Financial news for EXEL dated on 2016-08-03: Exelixis Reports Q2 EPS \$(0.16) vs. Est. \$(0.27), Rev. \$36.3M vs. Est. \$17.9M

Financial news for EXEL dated on 2016-06-30: Option Alert: SWEEP (SELL) - EXEL Jan \$8 Call - 1083 @ 1.0 in 20 orders. 1083 traded. OI: 827

Financial news for EXEL dated on 2016-06-22: Option Alert: EXEL Aug16 8.0 Calls: 500 @ ASK \$0.55: 1010 traded vs 3117 OI: Earnings 8/9 \$7.71 Ref

Financial news for EXEL dated on 2016-06-06: 9 Biggest Mid-Day Gainers For Monday

Financial news for EXEL dated on 2016-06-06: Stocks Hitting 52-Week Highs

Financial news for EXEL dated on 2016-06-06: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for EXEL dated on 2016-06-06: Pre Market Movers

Financial news for EXEL dated on 2016-06-06: Exelixis, Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting

Financial news for EXEL dated on 2016-06-05: Exelixis, Ipsen Announce Phase 3 Trial Results of CABOMETYX Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at #ASCO16

Financial news for EXEL dated on 2016-06-05: Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for Combination of Cobimetinib and Atezolizumab at #ASCO16

Financial news for EXEL dated on 2016-05-31: Option Alert: EXEL Jan18 7.0 Calls: 1397 @ ASK \$1.50: 1403 traded vs 3833 OI: \$6.58 Ref

Financial news for EXEL dated on 2016-05-23: Exelixis Offers Results from Randomized Phase 2 Trial of CABOSUN Showed Significant Improvement in Progression-Free Survival vs. Sunitinib

Financial news for EXEL dated on 2016-05-13: Mid-Afternoon Market Update: Dow Tumbles 1%; Nordstrom Shares Down Following Earnings Miss

Financial news for EXEL dated on 2016-05-11: Director Willsey Buys 60,000 Shares of Exelixis @\$4.97/Share -Form 4

Financial news for EXEL dated on 2016-04-28: IGlobe Capital Reports 6.14% Passive Stake in Exelixis in 13G

Financial news for EXEL dated on 2016-04-26: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2016-04-25: Exelixis Gets FDA Approval For Its CABOMETYX Tablets

Financial news for EXEL dated on 2016-04-25: Mid-Afternoon Market Update: Crude Oil Down 2%; KKR Shares Slide Following Q1 Results

Financial news for EXEL dated on 2016-04-25: Exelixis Confirms FDA Approval of CABOMETYX Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Financial news for EXEL dated on 2016-04-25: Exelixis PR Confirms FDA Approval of CABOMETYX Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Financial news for EXEL dated on 2016-04-25: Exelis CABOMETYX Gets FDA Approval For



## Renal Label

Financial news for EXEL dated on 2016-04-04: Option Alert: EXEL Aug16 7.0 Calls Sweep: 1575 @ ASK \$0.15: 1590 traded vs 5140 OI: Earnings 5/5 \$4.28 Ref

Financial news for EXEL dated on 2016-04-04: Exelixis Shares Up 5-6% Following Earlier Stifel Upgrade To Buy

Financial news for EXEL dated on 2016-03-28: Option Alert: EXEL May16 3.5 Calls: 952 @ Above Ask! \$0.70: 2000 traded vs 15 OI: Earnings 5/5 \$3.84 Ref

Financial news for EXEL dated on 2016-03-01: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for EXEL dated on 2016-02-29: 7 Stocks Moving In Today's After-Hours Session

Financial news for EXEL dated on 2016-02-29: Exelixis Inks Licensing Deal With Ipsen, ~\$855 Million

Financial news for EXEL dated on 2016-02-29: Exelixis Sees FY16 OpEx \$240M-\$270M

Financial news for EXEL dated on 2016-02-29: Exelixis Reports Q4 EPS \$(0.19) vs \$(0.22) Est., Sales \$9.9M vs \$8.2M Est.

Financial news for EXEL dated on 2016-02-29: Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan

Financial news for EXEL dated on 2016-01-28: Exelixis Reports EMA Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2016-01-28: Exelixis Reports FDA Has Deemed NDA Sufficiently Complete, Has Granted Priority Review for Cabozantinib for Treatment of Advance Renal Cell Carcinoma

Financial news for EXEL dated on 2016-01-19: Earlier Leerink Swann Upgraded Exelixis to Outperform

Financial news for EXEL dated on 2016-01-11: Exelixis Gives Marketing Authorization Application For Cabozantinib in EU For Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2016-01-05: Exelixis Spikes Following Phase 3 Results Of Cabozantinib; EU Filing Planned For Early 2016

Financial news for EXEL dated on 2016-01-05: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2016-01-05: 5 Stocks You Should Be Watching Today

Financial news for EXEL dated on 2016-01-04: Exelixis +11.52% After-Hours @\$6.14 Following Announcement of Positive Phase 3 Cabozantinib Trial Results

Financial news for EXEL dated on 2016-01-04: UPDATE: Exelixis Says EU Filing for Cabozantinib Planned for Early '16

Financial news for EXEL dated on 2016-01-04: Exelixis Reports Results from Subgroup Analyses of METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma: Data Further Underscores Clinical Benefit

Financial news for EXEL dated on 2015-12-23: Exelixis Completes Submission of New Drug Application for Cabozantinib for Advanced Renal Carcinoma Treatment

Financial news for EXEL dated on 2015-11-25: Exelixis Announces European Commission Approval of COTELLIC for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma

Financial news for EXEL dated on 2015-11-21: Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

Financial news for EXEL dated on 2015-11-10: Exelixis Reports Q3 EPS \$(0.22) vs. Est. \$(0.20), Rev. \$9.854M vs. Est. \$9.08M

Financial news for EXEL dated on 2015-11-10: Release from Daiichi Sankyo, Plexxikon Shows Co.'s to Co-Promote Cobimetinib in Combo with Zelboraf with Genentech, Exelixis

Financial news for EXEL dated on 2015-11-10: Exelixis to Resume Trading @2:00 PM ET

Financial news for EXEL dated on 2015-11-10: Exelixis Release Confirms FDA Approval of COTELLIC in Combo with Vemurafenib for Treatment of Advanced Melanoma

Financial news for EXEL dated on 2015-11-10: Roche's Genentech Confirms FDA Approval of Cotellic in Combo with Zelboraf in Advanced Melanoma

Financial news for EXEL dated on 2015-11-10: FDA Earlier Reported Approval of Roche, Exelixis' Cotellic for Combo Skin Cancer Therapy

Financial news for EXEL dated on 2015-11-10: Shares of Exelixis Halted News Pending

Financial news for EXEL dated on 2015-11-10: FDA Approves Cotellic as Part of Combination Treatment for Advanced Melanoma

Financial news for EXEL dated on 2015-10-22: Exelixis Begins Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer

Financial news for EXEL dated on 2015-10-06: Morning Market Gainers

Financial news for EXEL dated on 2015-10-06: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-10-06: Exelixis Announces Positive Overall Survival Results from coBRIM Phase 3 Pivotal Trial

Financial news for EXEL dated on 2015-09-28: Morning Market Losers

Financial news for EXEL dated on 2015-09-28: Benzinga's Top #PreMarket Losers

Financial news for EXEL dated on 2015-09-25: Exelixis Resumes Trading +18% Following Announcement of Positive Results from METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma

Financial news for EXEL dated on 2015-09-25: European CHMP Adopts Positive Opinion for Cobimetinib in Combination with Vemurafenib for the Treatment of Advanced Melanoma

Financial news for EXEL dated on 2015-09-16: Cramer's Stock To Buy After A Fed Rate Hike

Financial news for EXEL dated on 2015-09-16: Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, Marathon Oil, Exelixis

Financial news for EXEL dated on 2015-08-27: William Blair's Best Ideas In A Volatile Market

Financial news for EXEL dated on 2015-08-27: Morning Market Gainers

Financial news for EXEL dated on 2015-08-27: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-08-27: Exelixis +10% Premarket Following Announcement of Regulatory Approval of Cobimetinib in Switzerland

Financial news for EXEL dated on 2015-08-27: Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland

Financial news for EXEL dated on 2015-08-25: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-08-24: FDA Grants Breakthrough Therapy Designation to Exelixis' Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy

Financial news for EXEL dated on 2015-08-11: Exelixis Reports Q2 Loss of \$0.22/Share vs Loss of \$0.21/Share Est., Sales \$8M vs \$8.7M Est.

Financial news for EXEL dated on 2015-07-23: Exelixis Prices 25M Share Offering @\$5.40/Share

Financial news for EXEL dated on 2015-07-21: Morning Market Losers

Financial news for EXEL dated on 2015-07-21: Benzinga's Top #PreMarket Losers

Financial news for EXEL dated on 2015-07-20: Market Update: Monday's Mid-Day Movers; Greece Opens Banks; Gold Dwindles

Financial news for EXEL dated on 2015-07-20: Mid-Morning Market Update: Markets Mostly Flat; Morgan Stanley Beats Q2 Views

Financial news for EXEL dated on 2015-07-20: Morning Market Gainers

Financial news for EXEL dated on 2015-07-20: Exelixis Up 50% After Meteoric METEOR Results

Financial news for EXEL dated on 2015-07-20: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-07-20: Exelixis Announces Positive Top-Line Results from METEOR, Phase 3 Pivotal Trial of Cabozantinib Vs. Everolimus in Patients with Metastatic Renal Cell Carcinoma

Financial news for EXEL dated on 2015-07-20: Exelixis Shares Halted, Says Study Met Primary Endpoint

Financial news for EXEL dated on 2015-07-15: Exelixis Names Chris Senner as Executive VP, CFO

Financial news for EXEL dated on 2015-07-15: Filing from Exelixis Shows Registration for Common Stock Offering

Financial news for EXEL dated on 2015-07-14: Hearing Positive Comments from Agora Financial in Exelixis

Financial news for EXEL dated on 2015-07-13: Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Financial news for EXEL dated on 2015-07-01: Exelixis Gives Update on Genentech's Pending New Drug Application for Cobimetinib, an Exelixis-Discovered Compound

Financial news for EXEL dated on 2015-06-29: Benzinga's Top #PreMarket Losers

Financial news for EXEL dated on 2015-06-20: Watch These 10 Stocks Over The Weekend

Financial news for EXEL dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for EXEL dated on 2015-06-01: Morning Market Gainers

Financial news for EXEL dated on 2015-06-01: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-06-01: Exelixis Shares Rise 19% Premarket Following Announcement of Positive Phase 2 Cabozantinib Results at ASCO

Financial news for EXEL dated on 2015-05-31: Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged NSCLC at ASCO

Financial news for EXEL dated on 2015-05-31: Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type NSCLC at ASCO

Financial news for EXEL dated on 2015-05-30: Exelixis Reports Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for Advanced Melanoma at ASCO

Financial news for EXEL dated on 2015-05-14: Stifel Talks 5 Biotech Stocks

Financial news for EXEL dated on 2015-04-21: Biotech Investors: May 29th Could Be A Big Day

Financial news for EXEL dated on 2015-04-09: Morning Market Gainers

Financial news for EXEL dated on 2015-04-09: Exelixis Says it Expects Top Line Trail Results in Q2 2015

Financial news for EXEL dated on 2015-04-09: Exelixis' Cabozantinib Given Fast Track Designation By FDA For Renal Cell Carcinoma

Financial news for EXEL dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for EXEL dated on 2015-03-02: Exelixis Spikes Higher

Financial news for EXEL dated on 2015-02-24: Exelixis Reports Q4 Inline EPS -\$0.30, Sales \$7.35M Vs Est \$7.80M

Financial news for EXEL dated on 2015-02-19: Morning Market Gainers

Financial news for EXEL dated on 2015-02-19: Benzinga's Top #PreMarket Gainers

Financial news for EXEL dated on 2015-02-19: Roche's Genentech Announces FDA Grants Cobimetinib Priority Review for Use in Combination with Zelboraf in Advanced Melanoma

Financial news for EXEL dated on 2015-02-19: Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma

Financial news for EXEL dated on 2015-02-11: Exelixis Says Cabozantinib Could be a Franchise Unto Itself

Financial news for EXEL dated on 2015-02-11: Option Alert: Exelixis Feb \$2.5 Call; 2000 Contract Trade at Ask @\$0.15; Now \$2.36

Financial news for EXEL dated on 2015-02-05: Exelixis Data Release Upcoming; Options Activity Spiking

Financial news for EXEL dated on 2015-01-28: Notable Option Activity For January 28: MDR, STLD, JD, EXEL, MTW, CRUS

Financial news for EXEL dated on 2015-01-28: Option Alert: Exelixis May \$2 Call; 1790 Contract Trade at Ask @\$0.55; Now \$2.00

Financial news for EXEL dated on 2015-01-28: UPDATE: Exelixis Spokesperson Says Co has Already Stated They are Seeking Partner for Cabozantinib in RCC ex-U.S.; But have Not Announced Anything

Financial news for EXEL dated on 2015-01-28: Exelixis Spokesperson Says No News Released Today; Says Roche Reported this Morning, and There Were Several Mentions of Cobimetinib, The Partnered Program

Financial news for EXEL dated on 2015-01-28: Option Alert: Exelixis May \$3 Call; 1198 Contract Trade at Ask @\$0.30; Now \$1.98

Financial news for EXEL dated on 2015-01-28: Najarian Says Exelixis Could be Next Ziopharm, Intrexon-type Runner, Based on Call Activity

Financial news for EXEL dated on 2015-01-28: Option Alert: Exelixis May \$2 Call; 7818 Contract Trade at Ask @\$0.40; Now \$1.88

Financial news for EXEL dated on 2015-01-08: Option Alert: Exelixis Jan \$2 Call; 1,089 Contract Trade at Ask @\$0.10; Currently \$1.89

Financial news for EXEL dated on 2015-01-07: Exelixis, Swedish Orphan Biovitrum AB (Sobi) Extend And Restructure Distribution Agreement for COMETRIQ

Financial news for EXEL dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for EXEL dated on 2014-12-15: Genentech Submits NDA to FDA for Cobimetinib Used in Combination With Zelboraf in Advanced Melanoma

Financial news for EXEL dated on 2014-12-01: Mid-Day Market Update: ON Semiconductor Surges On \$1 Billion Buyback Plan; POZEN Shares Slip

Financial news for EXEL dated on 2014-12-01: Mid-Morning Market Update: Markets Open Lower; Weatherford To Sell Engineered Chemistry, Drilling Fluid Operations to Berkshire's Lubrizol

Financial news for EXEL dated on 2014-12-01: Morning Market Losers

Financial news for EXEL dated on 2014-12-01: Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib; Did Not Meet Primary Endpoint

Financial news for EXEL dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for EXEL dated on 2014-11-16: Exelixis Announces Positive Preliminary Data from Investigator-Sponsored Phase 1 Trial of XL888, Vemurafenib